FDA Extends Review Period for Valoctocogene Roxaparvovec for Hemophilia A

The FDA has extended the review period for the BLA for valoctocogene roxaparvovec for the treatment of hemophilia A in adults.

Related Keywords

, Hank Fuchs , Worldwide Research , Development Of Biomarin , Biologics License Application , Prescription Drug User Fee Act , Complete Response Letter ,